Skip to main content

Advertisement

SpringerLink
Log in

Therapie der rezidivierten und fernmetastasierten Kopf-Hals-Tumoren

Highlights des ASCO-Meetings 2016

Treatment of head and neck squamous cell carcinoma recurrences and distant metastases

Highlights of the ASCO Meeting 2016

  • Leitthema
  • Published:
HNO Aims and scope Submit manuscript

Zusammenfassung

Im Jahr 2016 wurden auf dem ASCO-Kongress insbesondere Ergebnisse von Phase-II-Studien präsentiert, in denen wie auch im Jahr zuvor der Einsatz neuerer Medikamente (monoklonale Antikörper, „small molecules“) bei Patienten mit rezidivierten und metastasierten Plattenepithelkarzinomen des Kopf-Hals-Bereichs (R/M HNSCC) eine große Rolle spielte. Auffällig war die große Zahl an Studien bez. des Nasopharynxkarzinoms. Die nun hier vorgestellten Studien geben die verschiedenen Konzepte der medikamentösen Behandlung von R/M HNSCC wider und repräsentiert die Vielfalt der Therapieansätze in der Rezidiv- und Metastasensituation.

Abstract

This year particularly phase II studies were presented at the 2016 ASCO Annual Meeting, in which new drugs (monoclonal antibodies, small molecules) were investigated in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC). Notably, there was a great number of studies investigating carcinoma of the nasopharynx. The studies presented in this article summarize the different therapeutic concepts in the treatment of R/M-HNSCC and represent the variety of therapeutic approaches in the recurrent and metastatic setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Ayyappan SR, Savvides P, Prabhakar D et al (2016) Correlation of hypomagnesemia from cetuximab with survival in metastatic squamous cell cancer of the head and neck (SCCHN). J Clin Oncol 34(suppl):abstr:6041

    Google Scholar 

  2. Baste N, Brana I, Viros D et al (2016) Impact of molecular prescreening for genomically-guided trials in head and neck cancer (HNC). J Clin Oncol 34(suppl):abstr:6030

    Google Scholar 

  3. Bhatia AK, Mehra R, Khan SA et al (2016) Phase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 34(suppl):abstr:6027

    Google Scholar 

  4. Harrington KJ, Forster MD, Dillon M et al (2016) Patritumab (P) or placebo (PBO) plus cetuximab (C) and platinum-based therapy in squamous cell carcinoma of the head and neck (SCCHN): a phase 2 study. J Clin Oncol 34(suppl):abstr:TPS6104

    Google Scholar 

  5. Keam B, Tahara M, Lin J‑C et al (2016) An international, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 2 study of palbociclib (an oral CDK4/6 inhibitor) plus cetuximab in patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 34(suppl):abstr:TPS6102

    Google Scholar 

  6. Leeman JE, Li J‑G, Venigalla P et al (2016) Natural history following recurrence after definitive locoregional treatment in 1000+ cases of locally advanced head and neck squamous cell carcinoma. J Clin Oncol 34(suppl):abstr:6062

    Google Scholar 

  7. Licitra LF, Faivre SJ, Chol M et al (2016) BERIL-1: Biomarker results from targeted sequencing of circulating tumor DNA (ctDNA) and archival tissue in a randomized phase II study of buparlisib (BKM120) or placebo plus paclitaxel in patients with head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 34(suppl):abstr:6045

    Google Scholar 

  8. Lopez-Pousa A, Sumarroca A, Quer M et al (2016) Risk of distant metastases in head and neck carcinoma patients and myeloperoxidase (MPO) expression. J Clin Oncol 34(suppl):abstr:6067

    Google Scholar 

  9. Mesia R, Bossi P, Hansen AR et al (2016) Interim results from a phase II study of CC-486 in previously treated patients (pts) with locally advanced/metastatic nasopharyngeal cancer (NPC). J Clin Oncol 34(suppl):abstr:6029

    Google Scholar 

  10. Prawira A, Oosting S, Chen TW-W et al (2016) Systemic therapies for recurrent/metastatic nasopharyngeal carcinoma (RM NPC). J Clin Oncol 34(suppl):abstr:6031

    Google Scholar 

  11. Rischin D, Boyer MJ, Brzezniak CE et al (2016) A phase 2 study of tarloxotinib bromide (TRLX) in patients (Pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS). J Clin Oncol 34(suppl):abstr:TPS6105

    Google Scholar 

  12. Soulieres D, Faivre SJ, Mesia R et al (2016) BERIL-1: A phase II, placebo-controlled study of buparlisib (BKM120) plus paclitaxel in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 34(suppl):abstr:6008

    Google Scholar 

  13. Tahara M, Kiyota N, Yokota T et al (2016) Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). J Clin Oncol 34(suppl):abstr:6026

    Google Scholar 

  14. Tan CS, Wang TT, Lim C‑M et al (2016) Randomised study of 2 low doses of sunitinib to modulate tumor microvasculature prior to chemotherapy in nasopharyngeal carcinoma (NPC). J Clin Oncol 34(suppl):abstr:6034

    Google Scholar 

  15. Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127

    Article  CAS  PubMed  Google Scholar 

  16. Wan X, Fan X (2016) Molecular decision tree algorithms to predict individual recurrence pattern for locally advanced nasopharyngeal carcinoma. J Clin Oncol 34(suppl):abstr:6046

    Google Scholar 

  17. Zhang L, Yu G, Jia J et al (2016) Gemcitabine plus cisplatin (GP) versus 5‑FU plus cisplatin (FP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC): A randomized, open-label, multicenter, phase III trial. J Clin Oncol 34(suppl):abstr:6007

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Kopf-Hals-Chirurgie und Onkologie, Kopf-Hals-Tumorzentrum des UCCH, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland

    L. Bußmann, C.-J. Busch &  R. Knecht

Authors
  1. L. Bußmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C.-J. Busch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Knecht
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Knecht.

Ethics declarations

Interessenkonflikt

L. Bußmann und C.-J. Busch geben an, dass kein Interessenkonflikt besteht. R. Knecht gibt folgende Interessenskonflikte an: Advisory Board BMS, AstraZeneca, Aventis und Merck Serono.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bußmann, L., Busch, CJ. & Knecht, R. Therapie der rezidivierten und fernmetastasierten Kopf-Hals-Tumoren . HNO 64, 723–730 (2016). https://doi.org/10.1007/s00106-016-0235-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00106-016-0235-6

Schlüsselwörter

Keywords

Search

Navigation